Cargando…

Combined immunotherapy with anti-PDL-1/PD-1 and anti-CD4 antibodies cures syngeneic disseminated neuroblastoma

Anti-PD-1 or anti-PD-L1 blocking monoclonal antibodies (mAbs) have shown potent anti-tumor effects in adult cancer patients and clinical studies have recently been started in pediatric cancers, including high-risk/relapsing neuroblastoma (NB). Therefore, we studied the effects of anti-PD-1/PD-L1 mAb...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rigo, Valentina, Emionite, Laura, Daga, Antonio, Astigiano, Simonetta, Corrias, Maria Valeria, Quintarelli, Concetta, Locatelli, Franco, Ferrini, Silvano, Croce, Michela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5656588/ https://www.ncbi.nlm.nih.gov/pubmed/29070883 http://dx.doi.org/10.1038/s41598-017-14417-6

Ejemplares similares

IL-10 and ARG-1 Concentrations in Bone Marrow and Peripheral Blood of Metastatic Neuroblastoma Patients Do Not Associate with Clinical Outcome
por: Morandi, Fabio, et al.
Publicado: (2015)

Different Subcellular Localization of ALCAM Molecules in Neuroblastoma: Association with Relapse
por: Corrias, Maria Valeria, et al.
Publicado: (2010)

BTK Inhibition Reverses MDSC-Mediated Immunosuppression and Enhances Response to Anti-PDL1 Therapy in Neuroblastoma
por: Ishfaq, Mehreen, et al.
Publicado: (2021)

Expression of FOXP3, CD14, and ARG1 in Neuroblastoma Tumor Tissue from High-Risk Patients Predicts Event-Free and Overall Survival
por: Stigliani, Sara, et al.
Publicado: (2015)

Altered erythropoiesis and decreased number of erythrocytes in children with neuroblastoma
por: Morandi, Fabio, et al.
Publicado: (2017)

IL-21: A Pleiotropic Cytokine with Potential Applications in Oncology
por: Croce, Michela, et al.
Publicado: (2015)

Pharmacological tumor PDL1 depletion with chlorambucil treats ovarian cancer and melanoma: improves antitumor immunity and renders anti-PDL1-resistant tumors anti-PDL1-sensitive through NK cell effects
por: Bai, Haiyan, et al.
Publicado: (2023)

Engineered extracellular vesicles for concurrent Anti-PDL1 immunotherapy and chemotherapy
por: Chen, Yundi, et al.
Publicado: (2021)

PDL1 Expression on Plasma and Dendritic Cells in Myeloma Bone Marrow Suggests Benefit of Targeted anti PD1-PDL1 Therapy
por: Sponaas, Anne-Marit, et al.
Publicado: (2015)

Resistance Mechanisms of Anti-PD1/PDL1 Therapy in Solid Tumors
por: Lei, Qingyang, et al.
Publicado: (2020)

Immunotherapy for Soft Tissue Sarcomas: Anti-PD1/PDL1 and Beyond
por: Fazel, Mina, et al.
Publicado: (2023)

Polymorphonuclear myeloid-derived suppressor cells impair the anti-tumor efficacy of GD2.CAR T-cells in patients with neuroblastoma
por: Tumino, Nicola, et al.
Publicado: (2021)

Low-dose interferon-γ-producing human neuroblastoma cells show reduced proliferation and delayed tumorigenicity
por: Airoldi, I, et al.
Publicado: (2004)

Anti-PDL1 effect in squamous non-small cell lung cancer
por: Rahouma, Mohamed, et al.
Publicado: (2020)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Antitumor activity of the investigational B7-H3 antibody-drug conjugate, vobramitamab duocarmazine, in preclinical models of neuroblastoma
por: Brignole, Chiara, et al.
Publicado: (2023)

Mutually exclusive expression of DLX2 and DLX5/6 is associated with the metastatic potential of the human breast cancer cell line MDA-MB-231
por: Morini, Monica, et al.
Publicado: (2010)

Guadecitabine increases response to combined anti-CTLA-4 and anti-PD-1 treatment in mouse melanoma in vivo by controlling T-cells, myeloid derived suppressor and NK cells
por: Amaro, Adriana, et al.
Publicado: (2023)

Anti-PD1 and Anti-PDL1-Induced Hypophysitis: A Cohort Study of 17 Patients with Longitudinal Follow-Up
por: Levy, Manon, et al.
Publicado: (2020)

Integration of cancer stemness and neoantigen load to predict responsiveness to anti-PD1/PDL1 therapy
por: Luo, Kunpeng, et al.
Publicado: (2022)

Identification of GALNT14 as a novel neuroblastoma predisposition gene
por: De Mariano, Marilena, et al.
Publicado: (2015)

Anti-Tumor Effects of Bak-Proteoliposomes against Glioblastoma
por: Liguori, Lavinia, et al.
Publicado: (2015)

Combination of GD2-directed bispecific trifunctional antibody therapy with Pd-1 immune checkpoint blockade induces anti-neuroblastoma immunity in a syngeneic mouse model
por: Ivasko, Sara Marie, et al.
Publicado: (2023)

Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12
por: Barker, S E, et al.
Publicado: (2007)

S49. Clinical activity and development of biomarkers for an engineered anti PDL1 antibody MPDL3280A
por: Cha, E
Publicado: (2014)

Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment()()
por: Vander Jagt, Thomas A., et al.
Publicado: (2018)

Successful osimertinib rechallenge following drug-induced pneumonitis after previous anti-PDL1 exposure
por: Harada, Guilherme, et al.
Publicado: (2019)

Combined mitoxantrone and anti-TGFβ treatment with PD-1 blockade enhances antitumor immunity by remodelling the tumor immune landscape in neuroblastoma
por: Lucarini, Valeria, et al.
Publicado: (2022)

TILs and Anti-PD1 Therapy: An Alternative Combination Therapy for PDL1 Negative Metastatic Cervical Cancer
por: Yin, Huanhuan, et al.
Publicado: (2020)

CSF1/CSF1R Axis Blockade Limits Mesothelioma and Enhances Efficiency of Anti-PDL1 Immunotherapy
por: Magkouta, Sophia Fotiou, et al.
Publicado: (2021)

Identification of PDL1-Related Biomarkers to Select Lung Adenocarcinoma Patients for PD1/PDL1 Inhibitors
por: Wu, Yanping, et al.
Publicado: (2020)

Preclinical Pharmacokinetics and Dosimetry of an (89)Zr Labelled Anti-PDL1 in an Orthotopic Lung Cancer Murine Model
por: Krache, Anis, et al.
Publicado: (2022)

m6A methylation regulators as predictors for treatment of advanced urothelial carcinoma with anti-PDL1 agent
por: Kong, Jianqiu, et al.
Publicado: (2022)

Cross-talk between microbiota and immune fitness to steer and control response to anti PD-1/PDL-1 treatment
por: Botticelli, Andrea, et al.
Publicado: (2016)

Enhanced anti-tumor activity of a new curcumin-related compound against melanoma and neuroblastoma cells
por: Pisano, Marina, et al.
Publicado: (2010)

The Olive Leaves Extract Has Anti-Tumor Effects against Neuroblastoma through Inhibition of Cell Proliferation and Induction of Apoptosis
por: Morandi, Fabio, et al.
Publicado: (2021)

Synthesis of Novel Peptide Dendrimers PDL-GB2 and PDL-G2
por: Yunzhu, Lin, et al.
Publicado: (2015)

Trends in the Research Into Immune Checkpoint Blockade by Anti-PD1/PDL1 Antibodies in Cancer Immunotherapy: A Bibliometric Study
por: Sun, Yiting, et al.
Publicado: (2021)

Research Trends and Most Influential Clinical Studies on Anti-PD1/PDL1 Immunotherapy for Cancers: A Bibliometric Analysis
por: Liu, Yanhao, et al.
Publicado: (2022)

Efficacy and Safety of Anti-PD1/PDL1 in Advanced Biliary Tract Cancer: A Systematic Review and Meta-Analysis
por: Jiang, Qi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_q36vbeshr0lrh6iphe85f1859n